Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Leveljump HealthcareTSXV:JUMP Days Payable is 91.97 as of Mar. 2026, which is 32% above its 10-year median of 69.43. The stock has 1 warning sign investors should review. Among 189 Medical Diagnostics & Research companies, Leveljump Healthcare ranks better than 56.61% on this metric.
The historical rank and industry rank for Leveljump Healthcare's Days Payable or its related term are showing as below:
TSXV:JUMP'
s Days Payable Range Over the Past 10 Years
Min: 45.33 Med: 69.43 Max: 86.39
Current: 86.25
During the past 7 years, Leveljump Healthcare's highest Days Payable was 86.39. The lowest was 45.33. And the median was 69.43.
TSXV:JUMP's Days Payable is ranked better than 56.61% of 189
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.8
vs TSXV:JUMP: 86.25
Leveljump Healthcare's Days Payable
increased
from Mar. 2025 (87.84) to Mar. 2026 (91.97).
It may suggest that Leveljump Healthcaredelayed paying its suppliers.
Leveljump Healthcare Days Payable Related Terms
Leveljump Healthcare Days Payable Historical Data
* Premium members only.
The historical data trend for Leveljump Healthcare's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:JUMP vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Leveljump Healthcare's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leveljump Healthcare Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Leveljump Healthcare's Days Payable distribution charts can be found below:
* The bar in red indicates where Leveljump Healthcare's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Leveljump Healthcare's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leveljump Healthcare (TSXV:JUMP) has a Days Payable of 91.97 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Leveljump Healthcare and its competitors. This is 32% above median its historical median of 69.43. Over the past decade, Leveljump Healthcare's Days Payable has ranged from 45.33 to 86.39. According to the industry distribution chart, Leveljump Healthcare ranks #82 out of 189 companies in the Medical Diagnostics & Research industry, placing it in the top 43.4%.
Is Leveljump Healthcare's Days Payable too high?
Leveljump Healthcare's current Days Payable of 91.97 is 32% above median its 10-year median of 69.43. Over the past 10 years, this metric has ranged from a low of 45.33 to a high of 86.39. The Medical Diagnostics & Research industry median Days Payable is 64.80. Leveljump Healthcare's value of 91.97 is 41.9% above this industry median. Based on the distribution chart, Leveljump Healthcare ranks #82 out of 189 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Leveljump Healthcare's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Leveljump Healthcare ranks #82 out of 189 companies for Days Payable. This puts Leveljump Healthcare in the upper half of its industry. The industry median Days Payable is 64.80. Leveljump Healthcare's value of 91.97 is 41.9% above this benchmark. Historically, Leveljump Healthcare's own Days Payable has ranged from 45.33 to 86.39 over the past decade. While the company's 10-year median is 69.43 vs. the industry median of 64.80, Leveljump Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.80, based on 189 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Leveljump Healthcare's current Days Payable of 91.97 is 41.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Leveljump Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Leveljump Healthcare's current Days Payable is 91.97, which is 32% above median its own 10-year median of 69.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Leveljump Healthcare stock overvalued right now?
Leveljump Healthcare (TSXV:JUMP) has a current Days Payable of 91.97. The stock's GF Value™ is C$0.07, compared to a current price of C$0.06 — trading 21.4% below its estimated fair value. The current Days Payable is 91.97, which is 32% above median its 10-year median of 69.43 and 41.9% above the Medical Diagnostics & Research industry median of 64.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Leveljump Healthcare (TSXV:JUMP), the current Days Payable is 91.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Leveljump Healthcare Corp is engaged in providing radiology services both by providing direct patient images and by providing Teleradiology services, which is the process of providing remote off-site reading of radiology scans such as CT, MRI, and X-ray. Its teleradiology services allow hospital staff to scan their emergency room patients, then page the company's radiologist on call, who can then remotely view, via a secured server, the images and diagnose the patient, and provide a report back to the hospital. Leveljump provides its direct-to-patient services at its Independent Healthcare Facilities (IHFs). The company operates as a single segment, with all of its core assets, intellectual property, and development work being conducted in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:JUMP has been successfully added to your 
